Merck Serono research brings a balance of small molecules, proteins and monoclonal antibodies into the early clinical development
pipeline. A broad base of technological expertise allows us to exploit the full potential of the biological and chemical spheres.
The application of new technologies and a broader platform of therapeutic molecules, enhanced by combined experience, is a
key factor for innovation.
Our integrated drug discovery process allows a disease-oriented approach, selecting the therapeutic method best suited to
treat that disease. Our objective is to bring the best compound to the clinic by a clear Proof-of-Concept strategic approach
in order to obtain a confirmed mode of action on patients.
Our research strategy is also supported by strong portfolio and business development from the discovery phase. Our network
of alliances with other biotech companies and academic groups fosters a constant flow of innovations into the organization
by enriching our disease knowledge and technological capabilities.
Our strong Therapeutic Area-focused drug discovery and development process includes specific disease-related scientific and
experimental expertise. A profound understanding of specific disease pathophysiology and related models is essential for successful
drug discovery.
- In Oncology, our goal is to develop novel therapies that specifically target cancer cells and are more tolerable for patients.
Our research is focused on all aspects of disease pharmacology in the Oncology area with the ultimate goal to increase patient
survival and improve quality of life.
- We focus on all aspects of disease biology and pharmacology research in the Neurodegenerative, Autoimmune and Inflammatory
disease areas with the goal to identify novel therapies that provide symptomatic relief and improve quality of life, slow
or stop disease progression.
- In Fertility, we are building a portfolio of therapeutic proteins and technologies for improving convenience and success rates
for patients undergoing in vitro fertilization.